Clinical Trial Update: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating nab-paclitaxel and gemcitabine with or without SBP-101 in metastatic pancreatic ductal adenocarcinoma; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• SBP-101 (SBP-101 (polyamine analog))

Snippet

Sponsor: Panbela Therapeutics, Inc. | Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma | Phase 2, Phase 3 | Status: RECRUITING